马坤岭
博士生导师 东南大学附属中大医院肾脏科
联系电话： 办公时间：8：00-17：30
传 真： 主页网址：
办公地点：东南大学附属中大医院肾科（医院2号楼9楼） 电子邮箱：klma05@163.com
通讯地址：南京市丁家桥87号












研究方向


主要从事糖、脂代谢紊乱介导靶器官损害的基础与临床研究，近年来主要聚焦糖尿病肾病、动脉粥样硬化等疾病早期发病机制，尤其是针对细胞及肠道菌群来源的微粒在其中发挥的作用进行了深入探索，临床研究注重从大数据入手分析疾病的发生、发展规律，探讨其在临床转化中的作用和科学意义。





荣誉奖励



马坤岭，英国伦敦大学（UCL）医学博士，教授，博士生导师、副主任医师，东南大学附属中大医院大内科副主任、肾科副主任，肾脏病研究所副所长，中国药理学会肾脏病药理专委会常务委员，中国病理生理学会肾脏病理生理专委会委员，中国生物化学与分子生物学会脂质与脂蛋白专业委员会委员，江苏省医师协会肾病专科分会委员，中华医学会肾脏病专科分会第10届青年委员。江苏省医学重点人才，江苏省“333工程”培养人选，江苏省“六大人才高峰”培养人选，江苏省优秀硕士生论文指导老师,东南大学优博基金指导老师。国家自然科学基金通讯评议专家，教育部学位论文评审专家，科技部项目评审专家库成员。主要从事糖、脂代谢紊乱在肾脏等靶器官损害中的基础与临床研究，先后主持国家自然科学基金课题4项，省部级课题6项。近年来获先后获得教育部自然科学奖一等奖、教育部科技进步奖二等奖、中华医学科技奖三等奖、江苏省科技进步奖二等奖、江苏省医学科技奖二等奖、南京市科技进步奖二等奖、浙江省科技进步奖一等奖、华夏医学科技奖三等奖等政府成果奖励8项。多次受邀在国际学术会议做大会发言。截至目前，以第一或通讯作者在J Am Soc Nephrol、??Theranostics??、Hepatology、Cardiovasc Res等国际权威杂志累计发表SCI收录论文33篇。





学术成果


近年来发表的主要论著:
1). LuCC, Hu ZB, Wang R, Hong ZH, Lu J, Chen PP, Zhang JX, Li XQ, Yuan BY, Huang SJ,Ruan XZ, Liu BC, Ma KL^(*). Gut microbiota dysbiosis-inducedactivation of the intrarenal renin-angiotensin system is involved in kidneyinjuries in rat diabetic nephropathy. Acta Pharmacol Sin 2020 Mar 17. doi:10.1038/s41401-019-0326-5. [Epub ahead of print]. (IF=4.01).
2). Hu ZB, Lu J, Chen PP, Lu CC, Zhang JX, Li XQ, YuanBY, Huang SJ, Ruan XZ, Liu BC, Ma KL^(*). Dysbiosis of intestinal microbiota mediatestubulointerstitial injury in diabetic nephropathy via the disruption ofcholesterol homeostasis. Theranostics 2020;10(6):2803-2816. (IF=8.063).
3) Lu J, Hu ZB, Chen PP, Lu CC, Zhang JX, Li XQ, Yuan BY, Huang SJ, *MaKL. Urinary levels of podocyte-derived microparticles are associated withthe progression of chronic kidney disease. Ann Transl Med. 2019 Sep;7(18):445. (IF=3.689).
4) Lu J, Hu ZB, Chen PP, Lu CC, Zhang JX, Li XQ, Yuan BY, Huang SJ, *MaKL. Urinary podocyte microparticles are associated with disease activityand renal injury in systemic lupus erythematosus. BMC Nephrol. 2019 Aug5;20(1):303. (IF=2.088).
5). *Ma KL, Liu L, Zhang Y, Wang GH, Hu ZB, Chen PP, Lu J, Lu CC,Gong TK, Gong YX, Liu BC. Aspirin attenuates podocyte injury in diabetic ratsthrough overriding cyclooxygenase-2-mediated dysregulation of LDL receptorpathway. Int Urol Nephrol. 2019 Mar;51(3):551-558. (IF=1.596)
6). Wang GH, *Ma KL, Zhang Y, Hu ZB, Liu L, Lu J, Chen PP, Lu CC,Ruan XZ, Liu BC. Caspase 3/ROCK1 pathway mediates high glucose-induced plateletmicroparticles shedding. Biochem Biophys Res Commun. 2019 Feb 5;509(2):596-602.(IF=2.705)
7). Wang GH, *Ma KL, Zhang Y, Hu ZB, Liu L, Lu J, Chen PP, Lu CC, Ruan XZ, LiuBC. Platelet microparticles contribute to aorticvascular endothelial injury in diabetes via the mTORC1 pathway. Acta Pharmacol Sin. 2019Apr;40(4):468-476. (IF=4.01).
8) Wang GH, Lu J, *Ma KL, ZhangY, Hu ZB, Chen PP, Lu CC, Zhang XL, Liu BC. TheRelease of Monocyte-Derived Tissue Factor-Positive Microparticles Contributesto a Hypercoagulable State in Idiopathic Membranous Nephropathy. J Atheroscler Thromb. 2019Jun 1;26(6):538-546. (IF=3.478).
9) Zhang Y, *Ma KL, Gong YX,Wang GH, Hu ZB, Liu L, Lu J, Chen PP, Lu CC, Ruan XZ, Liu BC. Platelet Microparticles Mediate Glomerular Endothelial Injury in EarlyDiabetic Nephropathy. J Am Soc Nephrol. 2018;29(11):2671-2695.(IF=8.547).
10). *Ma KL, GongTK, Hu ZB, Zhang Y, Wang GH, Liu L, Chen PP, Lu J, Lu CC, Liu BC.Lipoprotein(a) accelerated the progression of atherosclerosis in patients withend-stage renal disease. BMC Nephrol. 2018;19(1):192. (IF=2.088).
11) *Ma KL, Wu Y, Zhang Y, Wang GH, Hu ZB,Ruan XZ. Activation of the CXCL16/CXCR6 pathway promotes lipid deposition infatty livers of apolipoprotein E knockout mice and HepG2 cells. Am J TranslRes. 2018;10(6):1802-1816. (IF=3.266).
12) Lu CC, *Ma KL, Ruan XZ, Liu BC. Intestinal dysbiosis activatesrenal renin-angiotensin system contributing to incipient diabetic nephropathy.Int J Med Sci. 2018;15(8):816-822. (IF=2.333).
13) Hu ZB, *Ma KL, Zhang Y, Wang GH, Liu L, Lu J, Chen PP, Lu CC,Liu BC. Inflammation-activated CXCL16 pathway contributes to tubulointerstitialinjury in mouse diabetic nephropathy. Acta Pharmacol Sin. 2018;39(6):1022-1033.(IF=4.01).
14) Lu CC, *Ma KL, Ruan XZ, Liu BC. The Emerging Roles ofMicroparticles in Diabetic Nephropathy. Int J Biol Sci. 2017 Sep5;13(9):1118-1125. (IF=4.067).
15). #Hu ZB, #Chen Y, Gong YX, Gao M, Zhang Y, Wang GH, Tang RN, Liu H, LiuBC, *Ma KL. Activation of theCXCL16/CXCR6 Pathway by Inflammation Contributes to Atherosclerosis in Patientswith End-stage Renal Disease. Int J Med Sci.2016;13(11):858-867. (IF=2.333).
16）WuY, *Ma KL, Zhang Y, Wen Y, Wang GH, Hu ZB, Liu L, Lu J, Chen PP, RuanXZ, Liu BC. Lipid disorder and intrahepatic renin-angiotensin system activationsynergistically contributes to non-alcoholic fatty liver disease. Liver Int. 2016;36(10):1525-34.（IF=5.542）
17）ZhangY, *Ma KL, Ruan XZ, Liu BC. Dysregulation of the Low-Density LipoproteinReceptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury. Int JBiol Sci. 2016; 12(5):569-79. (IF=4.067)
18). *Ma KL, Zhang Y, Liu J, Wu Y, Hu ZB,Liu L, Liu BC. Inflammatory stress induces lipid accumulation in multi-organsof db/db mice. Acta Biochim Biophys Sin (Shanghai). 2015; 47(10): 767-74. (IF=2.502).
19). Zhang Y,* Ma KL, Liu J, Wu Y, Hu ZB, Liu L, Liu BC. Dysregulationof low-density lipoprotein receptor contributes to podocyte injuries indiabetic nephropathy. Am J Physiol Endocrinol Metab. 2015; 308(12):E1140-8.(IF=4.125).
20). Zhang Y, *Ma KL, Liu J, Wu Y, Hu ZB, Liu L, Lu J, Zhang XL, LiuBC. Inflammatory stress exacerbates lipid accumulation and podocyte injuries indiabetic nephropathy. Acta Diabetol. 2015; 52(6):1045-56. (IF=2.996).
21).Liu J, *Ma KL, Zhang Y, Wu Y, Hu ZB, Lv LL, Tang RN, Liu H, Ruan XZ, LiuBC. Activation of mTORC1disrupted LDL receptor pathway: a potential new mechanism for the progressionof non-alcoholic fatty liver disease. Int J Biochem Cell Biol. 2015; 61:8-19.(IF=3.144)
22). *Ma KL, Zhang Y,Liu J, Wu Y, Hu ZB, Ruan XZ, Liu BC. Establishment of an Inflamed Animal Modelof Diabetic Nephropathy. Int J Biol Sci 2014; 10(2):149-159.(IF=4.067)
23). Ma KL,LiuJ, Gao M, Wang CX, Ni J, Zhang Y,Zhang XL, Liu H, Wang YL, *Liu BC. Activation of mTOR contributes to foam cell formation in the radialarteries of patients with end-stage renal disease. ClinNephrol. 2014; 81(6)：396-404.（IF=1.079）
24). Ma KL, Ni J,Wang CX, Liu J, Zhang Y, Wu Y, Lv LL, Ruan XZ, *Liu BC. Interaction of RASActivation and Lipid Disorders Accelerates the Progression ofGlomerulosclerosis. Int JMed Sci 2013; 10(12):1615-24. (IF=2.333)
25). Ma KL, Liu J,Wang CX, Ni J, Zhang Y, Wu Y, Lv LL, Ruan XZ, Liu BC. Activation of mTORmodulates SREBP-2 to induce foam cell formation through increasedretinoblastoma protein phosphorylation. Cardiovasc Res 2013; 100(3):450-60. (IF=7.014).
26). Ni J, *Ma KL,Wang CX, Liu J, Zhang Y, Lv LL, Ni HF, Chen YX, Ruan XZ, Liu BC. Activation ofrenin-angiotensin system is involved in dyslipidemia-mediated renal injuries inapolipoprotein E knockout mice and HK-2 cells. Lipids Health Dis 2013; 12(1):49. (IF=2.651).
27). Ma KL, Liu J, NiJ, Zhang Y, Lv LL, Tang RN, Ni HF, Ruan XZ, *Liu BC. Inflammatory stressexacerbates the progression of cardiac fibrosis in high-fat-fed apolipoproteinE knockout mice via endothelial-mesenchymal transition. Int JMed Sci 2013; 10(4):420-6. (IF=2.333).
28). *Ma KL, Wang CX.Analysis of the spectrum and antibiotic resistance of uropathogens in vitro:results based on a retrospective study from a tertiary hospital. Am J Infect Control2013; 41(7):601-6. (IF=1.971)
29). Liu J, *Ma KL,Gao M, Wang CX, Ni J, Zhang Y, Zhang XL, Liu H, Wang YL, Liu BC. Inflammationdisrupts the LDL receptor pathway and accelerates the progression of vascularcalcification in ESRD patients. PLoS One 2012;7(10):e47217.(IF=2.776).
30). Ma KL, VargheseZ, Ku Y, Powis SH, Chen Y, Moorhead JF, *Ruan XZ. Sirolimus inhibits endogenouscholesterol synthesis induced by inflammatory stress in human vascular smoothmuscle cells. Am J Physiol Heart Circ Physiol 2010; 298(6):H1646-51.(IF=4.048).
31). Ma KL, *RuanXZ, Powis SH, Chen YX, Moorhead JF, andVarghese Z. Inflammatory stress exacerbates lipid accumulation in hepatic cellsand fatty livers of apolipoprotein E knockout mice. Hepatology 2008; 48 (3):770-81. (IF=14.971).
32). Ma KL, *Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Sirolimus modifies cholesterolhomeostasis in hepatic cells: a potential molecular mechanism forsirolimus-associated dyslipidemia. Transplantation 2007; 84(8):1029-36.(IF=4.593).
33). Ma KL, *Ruan XZ, Powis SH, Moorhead JF,and Varghese Z. Anti-atherosclerotic effects of sirolimus on human vascularsmooth muscle cells. Am J Physiol Heart Circ Physiol 2007; 292 (6):H2721-8.(IF=4.048).